
Cobenfy From Bristol Myers Squibb
The FDA has approved xanomeline and trospium chloride oral capsules (Cobenfy; Bristol Myers Squibb) for the treatment of schizophrenia in adults.1 Schizophrenia affects approximately 2.8 million individuals in the US and 24 million people around the globe, …